Data layers Raw facts Calculated Model prediction AI interpretation

Cross-Market Price Comparison

Other Listed Market Shanghai (SSE) — 药明康德
Other Market Stock Code603259
H-Share Offer PriceTo be extracted
Other Market PriceLoading...
Reference Exchange RateLoading...
H-Share Offer Price Premium/Discount vs Other MarketLoading...

Company Overview

Stock NameWuxi Apptec
Stock Code02359
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities全球領先的藥物研發服務平台,提供全面配套的研究及生產服務,全面覆蓋小分子藥物的發現、開發及生產流程,同時提供細胞及基因療法的研發和生產服務,並提供醫療器械檢測服務。
Listing Date2018-12-13
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國 上海 外高橋自貿區 富特中路288號
Business Address (Hong Kong)香港 皇后大道東183號 合和中心54樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.wuxiapptec.com.cn
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingYes (A股)

Offering Information

Offering Mechanism To be extracted
Offer PriceHK$ 68.00 / shares
Offer Price RangeTo be extracted
Lot Size100 shares
Entry ThresholdTo be extracted
Par ValueRMB 1.0 / shares
Offer Period2018-12-03 to 2018-12-06
Global Offering Shares116,474,200 shares
HK Public Offer Shares (Initial)11,647,600 shares (10.0%)
Public Offer Lots (Initial)116,476lots (Pool A58,238lots,Pool B58,238lots)
International Placing Shares (Initial)104,826,600 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO1,164,741,086 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionNo
Total Global Offering SizeHK$ 7,920,245,600

Stock Connect Inclusion Analysis

HK Market Cap HK$ 85.07B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣1,296.7百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 2015201620172018-06
Revenue 4,883,3496,116,1317,765,2604,409,207
Cost of sales -3,204,718-3,633,640-4,525,340-2,653,098
Gross profit 1,678,6312,482,4913,239,9201,756,109
Other income and gains, net 387,441236,873173,779444,361
Selling and distribution expenses -185,807-200,439-291,510-152,680
Administrative expenses -851,769-834,862-986,540-435,261
Operating profit 858,8671,441,0181,689,8071,440,652
Net finance costs -28,125-16,360-48,547-45,521
Share of associates and JVs -29,393-42,483-48,64029,900
Profit before tax 801,3491,382,1751,592,6201,425,031
Income tax expense -117,570-261,202-295,900-120,961
Profit for the year 683,7791,120,9731,296,7201,304,070
Profit attributable to owners 348,968974,9801,227,0931,271,898
Balance Sheet
Item 2015201620172018-06
Cash and cash equivalents 1,002,0652,507,2992,466,1441,380,355
Trade and bills receivables 1,240,6121,336,9011,752,8072,026,861
Inventories 208,411444,587649,815772,105
Total current assets 6,358,7136,043,7105,470,2017,401,966
Total assets 9,686,43110,590,68312,580,44716,140,664
Total current liabilities 2,992,1774,201,3454,619,4234,694,852
Total liabilities 3,256,3084,528,2785,842,4365,806,028
Total equity 6,430,1236,062,4056,738,01110,334,636
Equity attributable to owners 3,367,6675,569,1736,342,3809,922,001
Interest-bearing borrowings 172,000489,3851,618,1891,756,660
Cash Flow Statement
Item 2015201620172018-06
Net cash from operating activities 738,5961,761,3081,795,648420,733
Net cash from investing activities -933,281383,995-1,132,344-3,682,834
Net cash from financing activities 428,512-721,489-668,1772,201,402
Net increase in cash 233,8271,423,814-4,873-1,060,699
Depreciation of PP&E 359,492364,482439,896275,920
Amortisation of intangible assets 25,88633,16834,38421,382
Purchase of PP&E -896,771-933,899-1,352,467-739,505
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 68.0
First Day OpenHK$ 67.0
First Day Change88.09%
First Day Volume20214000.0
First Day Turnover1355050000.0
Use of Proceeds
1、約36.9%(即約2,798.0百萬港元)用于擴大全球所有業務單位的生產力及能力; 2、約26.5%(即約2,000.0百萬港元)用于收購CRO及CMO/CDMO公司; 3、約4.0%(即約300.0百萬港元)用于投資及培育健康業界有創新業務模式且有增長潛力的公司,以投資我們的生態體系; 4、約2.6%(即約200.0百萬港元)用于開發高端科技; 5、約19.9%(即約1,500百萬港元)用于償還最后可行日期的未償還選定銀行貸款; 6、約10.0%(即約755.3百萬港元)撥作營運資金及一般公司用途。

Underwriting Syndicate

Joint Sponsors (3)
Morgan Stanley Asia Limited CE AAD291 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
Overall Coordinators (5)
Morgan Stanley Asia Limited CE AAD291 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 UBS Securities Hong Kong Limited CE BIN466 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Joint Bookrunners (8)
Morgan Stanley Asia Limited CE AAD291 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 UBS Securities Hong Kong Limited CE BIN466 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 China Renaissance Securities (Hong Kong) Limited CE AZX839 中银国际亚洲有限公司 CE AET863 CLSA LIMITED CE AAB893

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman李革—
Company Secretary姚馳—
No director data available.

Major Shareholders

Major Shareholders & Holdings李革、趙寧、張朝暉、劉曉鐘為一致行動人,合共持有323,359,483股A股,佔約30.85%;其他主要股東包括G&C VI Limited(7.73%)、光輝月光有限公司(8.48%)、博裕系列(6.86%)、淡馬錫(7.77%)等。
About this page

This page shows Wuxi Apptec (02359) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect